NCT07528443Completed
Ultraprocessed Foods in Colombia
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
The study seeks to examine how characters on packaging and warning labels affect purchase intentions and risk perception among children aged 12 to 17 in Colombia and, examine whether characters' presence weakens or reduces the perceived message effectiveness of the warning labels' impact. This will be a 2x2 between-subjects experiment manipulating presence or absence of characters and presence or absence of warning labels. Participants will be randomly assigned to 1 of 4 conditions in an online survey programmed in Qualtrics.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2000 (actual)
- First submitted
- 7 Apr 2026
- Start date
- 25 Jun 2026
- Primary completion date
- 15 Aug 2026
- Lead sponsor
- University of North Carolina, Chapel Hill
- Diseases
- Obesity
- NCT number
- NCT07528443
What you commit to
- Study type: Interventional
- Participants enrolled: 2000
- From 25 Jun 2026 to the primary completion date, 15 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Children with legal blindness, partial blindness, or total blindness, since the study involves viewing images and reading questions.
Who the study is looking for
- Children and adolescents between 12 and 17 years old
- Colombian residents
Age in the registry: 12 years to 17 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Online panel Coordinator of this site? Confirm its status | Bogotá | Colombia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.